Edward Tenthoff analyst PIPER SANDLER

Currently out of the existing stock ratings of Edward Tenthoff, 634 are a BUY (90.31%), 56 are a HOLD (7.98%), 12 are a SELL (1.71%).

Edward Tenthoff

Work Performance Price Targets & Ratings Chart

Analyst Edward Tenthoff works at PIPER SANDLER with a stock forecast success ratio of 43.61% fulfilled within 225.33 days on average.

Edward Tenthoff’s has documented 1,385 price targets and ratings displayed on 76 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IPSC, Century Therapeutics at 12-Apr-2024.

Wall Street Analyst Edward Tenthoff

Analyst best performing recommendations are on MIST (MILESTONE PHARMACEUTICALS).
The best stock recommendation documented was for MIST (MILESTONE PHARMACEUTICALS) at 3/23/2020. The price target of $3 was fulfilled within 1 day with a profit of $11 (78.57%) receiving and performance score of 785.71.

Average potential price target upside

AGLE Aeglea Bio Therapeutics ALNY Alnylam Pharmaceuticals ALPN Alpine Immune Sciences APVO Aptevo Therapeutics ARAV Aravive ARGX argenx NV ADR ARVN Arvinas ARWR Arrowhead Pharmaceuticals AVEO AVEO Pharmaceuticals BCYC Bicycle Therapeutics Ltd CCXI ChemoCentryx CRSP Crispr Therapeutics AG CYTK Cytokinetics DYN Dyne Therapeutics  EXEL Exelixis FATE Fate Therapeutics GMDA Gamida Cell Ltd INFI Infinity Pharmaceuticals IPSC Century Therapeutics KLDO Kaleido Biosciences KYMR Kymera Therapeutics MCRB Seres Therapeutics MRKR Marker Therapeutics MRNA Moderna NVAX Novavax NXTC NextCure  OPK Opko Health PSTX Poseida Therapeutics PTI Proteostasis Therapeutics RAPT RAPT Therapeutics STRO Sutro Biopharma SYBX Synlogic SYRS Syros Pharmaceuticals TPST Tempest Therapeutics TTPH Tetraphase Pharmaceuticals XNCR Xencor LIFE aTyr Pharma SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals ARNA Arena Pharmaceuticals ASLN Aslan Pharmaceuticals Ltd ADR CBAY Cymabay Therapeu CHMA Chiasma EIGR Eiger Biopharmaceuticals ELOX Eloxx Pharmaceuticals FULC Fulcrum Therapeutics GNCA Genocea Biosciences JNCE Jounce Therapeutics LEGN Legend Biotech Corp LRMR Larimar Therapeutics MIST Milestone Pharmaceuticals FSTX FStar Therapeutics GLUE Monte Rosa Therapeutics KRON Kronos Bio  OMGA Omega Therapeutics PNT POINT Biopharma Global PRTC PureTech Health PLC SBPH Spring Bank Pharmaceuticals VCEL Vericel Corp Ord XOMA XOMA Corp ZFGN Zafgen APTO Aptose Biosciences GILD Gilead Sciences REGN Regeneron Pharmaceuticals SGEN Seagen XLRN Acceleron Pharma GRTS Gritstone Oncology XFOR X4 Pharmaceuticals CFRX ContraFect Corp IDRA Idera Pharmaceuticals KDMN Kadmon Holdings MTNB Matinas BioPharma Holdings ONCS OncoSec Medical MESO Mesoblast Ltd GRTX Galera Therapeutics CUE Cue Biopharma

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

12

$-15.6 (-56.52%)

12.5

5 months 24 days ago

3/3 (100%)

$1.82 (17.88%)

11

Buy

23

$-4.6 (-16.67%)

22.5

7 months 26 days ago

2/2 (100%)

$8.95 (63.70%)

141

Hold

25

$-2.6 (-9.42%)

25

1 years 2 months 4 days ago

2/4 (50%)

$15.15 (153.81%)

238

Hold

25

1 years 6 months 10 days ago

1/4 (25%)

$6.75 (36.99%)

151

Buy

11

1 years 11 months 4 days ago

2/2 (100%)

$3.33 (40.64%)

1025

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Edward Tenthoff is most bullish on?

Potential upside of $124.22 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Edward Tenthoff is most reserved on?

Potential downside of -$0.31 has been obtained for XNCR (XENCOR)

What Year was the first public recommendation made by Edward Tenthoff?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?